Cytokines and Chemokines in Erythema Migrans

• Status: Unknown status
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with erythema migrans to gain better insight into pathogenesis of early Lyme borreliosis and to define new immune modulators that could serve as biomarkers of disease activity.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Medical Centre Ljubljana
• Collaborators: Harvard University; Medical University of Vienna; University of Ljubljana School of Medicine, Slovenia
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular

Criteria

Inclusion Criteria:

• erythema migrans in patients > 18 years

Exclusion Criteria:

• pregnancy or lactation

• taking antibiotic with antiborrelial activity within 10 days